Journal of Clinical Oncology, Vol 14, 671-679, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

In 1993, the Health Services Research Committee of the American Society of Clinical Oncology (ASCO) charged an Outcomes Working Group with defining the outcomes of adult and pediatric cancer treatment to be used for technology assessment and development of cancer treatment guidelines. The Working Group defined by consensus outcomes for technology assessment and guideline development, focusing on cancer treatments. The Working Group considered a variety of perspectives on outcomes, including those of patients, physicians, clinical investigators, ASCO, and policy makers. Because ASCO's guidelines will define what constitutes the best treatment and not whether that treatment should be paid for, the Working Group gave higher priority to the clinical and clinical research perspectives than to the health policy perspective. Survival is the most important outcome of cancer treatment. An improvement in at least disease-free survival is a prerequisite for recommending adjuvant therapy. In the case of metastatic cancer, treatment can be recommended even without an improvement in survival, if it improves quality of life. Quality of life includes global quality of life, as well as its physical, psychologic, and social dimensions. To be an outcome of cancer treatment, quality-of-life measures must be sensitive to clinically meaningful changes produced by treatment; evaluations must control for placebo effects and determinants of quality of life not related to cancer or its treatment. Toxicity, both short and long term, is vitally important, with the latter being particularly critical in children. The value of cancer outcomes like tumor response (eg, complete or partial response) and biomarkers (eg, CA-125) for technology assessment and guideline development depends on their ability to predict patient outcomes (survival and quality of life) or to influence decisions about treatment. Complete response is an important outcome when it predicts survival. Progression is important because it signals the need to change or stop treatment. Cost-effectiveness is an especially important outcome to consider when the benefits of treatment are modest or the costs are high. Patient outcomes (eg, survival and quality of life) should receive higher priority than cancer outcomes (eg, response rate), but both types of outcomes are important in technology assessment and guideline development. Multiple outcomes should be considered because no single outcome adequately describes the results of cancer treatment. In general, there is no minimum benefit above which treatments are justified; rather, benefits should be balanced against toxicity and cost.

This article has been cited by other articles:

				S. E. Harrington and T. J. Smith The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?" JAMA, June 11, 2008; 299(22): 2667 - 2678. [Abstract] [Full Text] [PDF]

				J. L. Khatcheressian, A. C. Wolff, T. J. Smith, E. Grunfeld, H. B. Muss, V. G. Vogel, F. Halberg, M. R. Somerfield, and N. E. Davidson American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting J. Clin. Oncol., November 1, 2006; 24(31): 5091 - 5097. [Abstract] [Full Text] [PDF]

				G. T. Budd, M. Cristofanilli, M. J. Ellis, A. Stopeck, E. Borden, M. C. Miller, J. Matera, M. Repollet, G. V. Doyle, L. W.M.M. Terstappen, et al. Circulating Tumor Cells versus Imaging--Predicting Overall Survival in Metastatic Breast Cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6403 - 6409. [Abstract] [Full Text] [PDF]

				R. Matsuyama, S. Reddy, and T. J. Smith Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3490 - 3496. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				K. N. L. Avery, C. Metcalfe, J. Nicklin, C. P. Barham, D. Alderson, J. L. Donovan, and J. M. Blazeby Satisfaction With Care: An Independent Outcome Measure in Surgical Oncology Ann. Surg. Oncol., June 1, 2006; 13(6): 817 - 822. [Abstract] [Full Text] [PDF]

				D. Tassinari, B. Poggi, M. Fantini, E. Tamburini, S. Nicoletti, and S. Sartori Cost-opportunity analysis in clinical oncology: from the 'wild far-west' to a correct integration of the disciplines, avoiding the 'war of the worlds' Ann. Onc., May 1, 2006; 17(5): 876 - 877. [Full Text] [PDF]

				D. Tassinari, B. Poggi, E. Tamburini, M. Fantini, S. Nicoletti, and S. Sartori Quality of care in clinical oncology: from the dreamworld to the real world of outcome assessment Ann. Onc., January 1, 2006; 17(1): 177 - 178. [Full Text] [PDF]

				J. Ezzo, A. Vickers, M. A. Richardson, C. Allen, S. L. Dibble, B. Issell, L. Lao, M. Pearl, G. Ramirez, J. A. Roscoe, et al. Acupuncture-Point Stimulation for Chemotherapy-Induced Nausea and Vomiting J. Clin. Oncol., October 1, 2005; 23(28): 7188 - 7198. [Abstract] [Full Text] [PDF]

				J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410. [Abstract] [Full Text] [PDF]

				M.-F. Demierre, A. Tien, and D. Miller Health-Related Quality-of-Life Assessment in Patients With Cutaneous T-Cell Lymphoma Arch Dermatol, March 1, 2005; 141(3): 325 - 330. [Abstract] [Full Text] [PDF]

				D. R. Buchanan, A. M. O'Mara, J. W. Kelaghan, and L. M. Minasian Quality-of-Life Assessment in the Symptom Management Trials of the National Cancer Institute-Supported Community Clinical Oncology Program J. Clin. Oncol., January 20, 2005; 23(3): 591 - 598. [Abstract] [Full Text] [PDF]

				P. T. Truong, I. A. Olivotto, T. J. Whelan, and M. Levine Outcomes of postmastectomy radiotherapy Can. Med. Assoc. J., January 4, 2005; 172(1): 19 - 19. [Full Text] [PDF]

				N. Kalant Outcomes of postmastectomy radiotherapy Can. Med. Assoc. J., January 4, 2005; 172(1): 18 - 18. [Full Text] [PDF]

				W. Landier, S. Bhatia, D. A. Eshelman, K. J. Forte, T. Sweeney, A. L. Hester, J. Darling, F. D. Armstrong, J. Blatt, L. S. Constine, et al. Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline J. Clin. Oncol., December 15, 2004; 22(24): 4979 - 4990. [Abstract] [Full Text] [PDF]

				I. Chau, A. R. Norman, D. Cunningham, J. S. Waters, J. Oates, and P. J. Ross Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer--Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data J. Clin. Oncol., June 15, 2004; 22(12): 2395 - 2403. [Abstract] [Full Text] [PDF]

				S. Toth-Fejel, P. Muller, B. Ham, K. Esvelt, N. Dumas, K. Calhoun, and R. Pommier DNA Fingerprints Provide a Patient-Specific Breast Cancer Marker Ann. Surg. Oncol., June 1, 2004; 11(6): 560 - 567. [Abstract] [Full Text] [PDF]

				J.S. Burgers, B. Fervers, M. Haugh, M. Brouwers, G. Browman, T. Philip, and F.A. Cluzeau International Assessment of the Quality of Clinical Practice Guidelines in Oncology Using the Appraisal of Guidelines and Research and Evaluation Instrument J. Clin. Oncol., May 15, 2004; 22(10): 2000 - 2007. [Abstract] [Full Text] [PDF]

				C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]

				P. Harper, T. Plunkett, and D. Khayat Quality Trials and Quality of Life in Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2003; 21(16): 3007 - 3008. [Full Text] [PDF]

				D. Tassinari, I. Panzini, S. Sartori, and A. Ravaioli Surrogate Outcomes in Quality-of-Life Research: Where Will We End Up? J. Clin. Oncol., May 1, 2003; 21(9): 1894 - 1895. [Full Text] [PDF]

				J. A. Sloan Quality-of-Life Meta-Analysis: Why Treat It Differently? J. Clin. Oncol., April 1, 2003; 21(7): 1422 - 1422. [Full Text] [PDF]

				J. D. Rizzo, A. E. Lichtin, S. H. Woolf, J. Seidenfeld, C. L. Bennett, D. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, S. J. Lee, et al. Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology J. Clin. Oncol., October 1, 2002; 20(19): 4083 - 4107. [Abstract] [Full Text] [PDF]

				L. A. Santana-Blank, E. Rodriguez-Santana, F. Vargas, H. Reyes, P. Fernandez-Andrade, S. Rukos, and K. E. Santana-Rodriguez Phase I Trial of an Infrared Pulsed Laser Device in Patients with Advanced Neoplasias Clin. Cancer Res., October 1, 2002; 8(10): 3082 - 3091. [Abstract] [Full Text] [PDF]

				J. D. Rizzo, A. E. Lichtin, S. H. Woolf, J. Seidenfeld, C. L. Bennett, D. Cella, B. Djulbegovic, M. J. Goode, A. A. Jakubowski, S. J. Lee, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood, September 18, 2002; 100(7): 2303 - 2320. [Abstract] [Full Text] [PDF]

				E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002 J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327. [Abstract] [Full Text] [PDF]

				M. N. Levine and P. A. Ganz Beyond the Development of Quality-of-Life Instruments: Where Do We Go From Here? J. Clin. Oncol., May 1, 2002; 20(9): 2215 - 2216. [Full Text] [PDF]

				N. Heffernan, D. Cella, K. Webster, L. Odom, M. Martone, S. Passik, M. Bookbinder, Y. Fong, W. Jarnagin, and L. Blumgart Measuring Health-Related Quality of Life in Patients With Hepatobiliary Cancers: The Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire J. Clin. Oncol., May 1, 2002; 20(9): 2229 - 2239. [Abstract] [Full Text] [PDF]

				F. Cardoso, A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira, and M. J. Piccart Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann. Onc., February 20, 2002; 13(2): 197 - 207. [Abstract] [Full Text] [PDF]

				M. Koller and W. Lorenz Quality of life: a deconstruction for clinicians J R Soc Med, January 10, 2002; 95(10): 481 - 488. [Full Text] [PDF]

				T. J. Smith and B. E. Hillner Ensuring Quality Cancer Care by the Use of Clinical Practice Guidelines and Critical Pathways J. Clin. Oncol., June 1, 2001; 19(11): 2886 - 2897. [Abstract] [Full Text] [PDF]

				F. Recchia, S. De Filippis, M. Rosselli, G. Saggio, A. Cesta, L. Fumagalli, and S. Rea Phase 1B Study of Subcutaneously Administered Interleukin 2 in Combination with 13-cis Retinoic Acid as Maintenance Therapy in Advanced Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1251 - 1257. [Abstract] [Full Text]

				R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				S. B. Detmar, M. J. Muller, L. D. V. Wever, J. H. Schornagel, and N. K. Aaronson Patient-Physician Communication During Outpatient Palliative Treatment Visits: An Observational Study JAMA, March 14, 2001; 285(10): 1351 - 1357. [Abstract] [Full Text] [PDF]

				A. Recht, S. B. Edge, L. J. Solin, D. S. Robinson, A. Estabrook, R. E. Fine, G. F. Fleming, S. Formenti, C. Hudis, J. J. Kirshner, et al. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1539 - 1569. [Abstract] [Full Text] [PDF]

				T. J. Smith Tell It Like It Is J. Clin. Oncol., October 19, 2000; 18(19): 3441 - 3445. [Full Text] [PDF]

				S. B. Detmar, N. K. Aaronson, L. D. V. Wever, M. Muller, and J. H. Schornagel How Are You Feeling? Who Wants To Know? Patients' and Oncologists' Preferences for Discussing Health-Related Quality-of-Life Issues J. Clin. Oncol., September 15, 2000; 18(18): 3295 - 3301. [Abstract] [Full Text] [PDF]

				B. Norris, K. I. Pritchard, K. James, J. Myles, K. Bennett, S. Marlin, J. Skillings, B. Findlay, T. Vandenberg, P. Goss, et al. Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 J. Clin. Oncol., June 12, 2000; 18(12): 2385 - 2394. [Abstract] [Full Text] [PDF]

				D. Waldron, C. A. O'Boyle, M. Kearney, M. Moriarty, and D. Carney Quality-of-Life Measurement in Advanced Cancer: Assessing the Individual J. Clin. Oncol., November 1, 1999; 17(11): 3603 - 3611. [Abstract] [Full Text] [PDF]

				M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355. [Abstract] [Full Text] [PDF]

				J. S. Mandelblatt and K. R. Yabroff Effectiveness of Interventions Designed to Increase Mammography Use: A Meta-Analysis of Provider-targeted Strategies Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 759 - 767. [Abstract] [Full Text]

				J. S. Mandelblatt, P. A. Ganz, and K. L. Kahn Proposed Agenda for the Measurement of Quality-of-Care Outcomes in Oncology Practice J. Clin. Oncol., August 1, 1999; 17(8): 2614 - 2614. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939. [Abstract] [Full Text] [PDF]

				C. E. Desch, A. B. Benson III, T. J. Smith, P. J. Flynn, C. Krause, C. L. Loprinzi, B. D. Minsky, N. J. Petrelli, D. G. Pfister, and M. R. Somerfield Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology J. Clin. Oncol., April 1, 1999; 17(4): 1312 - 1312. [Abstract] [Full Text] [PDF]

				T. J. Smith, N. E. Davidson, D. V. Schapira, E. Grunfeld, H. B. Muss, V. G. Vogel III, and M. R. Somerfield American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines J. Clin. Oncol., March 1, 1999; 17(3): 1080 - 1080. [Abstract] [Full Text] [PDF]

				S. C. Malfair Taylor "C" is for costs, and cancer, and conference: Highlights of the First European Conference on the Economics of Cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 125 - 128. [Abstract] [PDF]

				C. C. Gotay and M. Wilson Use of Quality-of-Life Outcome Assessments in Current Cancer Clinical Trials Eval Health Prof, June 1, 1998; 21(2): 157 - 178. [Abstract] [PDF]